These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 9002758)

  • 41. 111In octreotide retention in the orbit of a patient with diabetic retinopathy.
    Aydin A; Durak H; Mavi A; Durak I
    Nuklearmedizin; 2004 Mar; 43(2):N21-2. PubMed ID: 15108682
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of carboxyl-group of D-glutamic acid or gamma-carboxy-D-glutamic acid as N-terminal amino acid of (111)in-diethylenetriaminepentaacetic acid-octreotide on accumulation of radioactivity in kidney.
    Akizawa H; Saito M; Tsukamoto I; Ohkura T; Shimizu T; Kitamura Y; Mifune M; Saito Y; Arano Y; Saji H
    Biol Pharm Bull; 2007 Nov; 30(11):2226-8. PubMed ID: 17978507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A two-compartmental model analysis of plasma clearance and urinary excretion data of 111In-DTPA in dogs.
    Saha GB; Boyd CM
    Int J Nucl Med Biol; 1982; 9(2):122-5. PubMed ID: 7107125
    [No Abstract]   [Full Text] [Related]  

  • 44. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
    Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
    Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiation dosimetry for indium-111-pentetreotide.
    Stabin MG; Kooij PP; Bakker WH; Inoue T; Endo K; Coveney J; de Jong R; Minegishi A
    J Nucl Med; 1997 Dec; 38(12):1919-22. PubMed ID: 9430470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Description of a multicompartmental model of the biodistribution of 111In-DTPA-D-Phe-1-octreotide in human.
    D'addabbo A; Simeone G; Rubini G; Nitti L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):86-9. PubMed ID: 9002758
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.